Signum Dermalogix seals partnership with Elizabeth Arden

By Katie Nichol

- Last updated on GMT

Signum Dermalogix seals partnership with Elizabeth Arden
US biopharmaceutical company Signum Dermalogix has sealed a partnership with prestige beauty products firm Elizabeth Arden concerning a semi-exclusive global license for its cosmetic functional ingredient Arazine.

According to Signum Dermalogix, Arazine was initially discovered at Princeton University and boasts anti-inflammatory and anti-oxidant properties.

Along with Idebenone-ester, it is a key ingredient in Elizabeth Arden’s Prevage Anti-aging + Intensive Repair Daily Serum, which the cosmetics firm claims improves the appearance of fine lines and 'lifts' the look of skin within 15 minutes. 

Arzine designed to mimic cellular activity

Maxwell Stock,​ president & CEO of Signum Dermalogix, told USA that “Arazine was designed to mimic the isoprenylcysteine (IPC) motif that occurs in multiple G proteins that interact with the intracellular domains of G protein- coupled receptors (GPCRs). These interactions regulate multiple processes, including the secretion of pro-inflammatory cytokines.”​ 

Arazine is the first cosmetic ingredient to be commercialized from Signum Dermalogix's novel technology platform. According to Stock, Arazine is also licensed to Rohto Pharmaceuticals for use in Japan only, and Signum Dermalogix has also kept the right to license the ingredient in the Physician Dispensed channel. 

Semi-global license and new screening methodologies​ 

In addition to the semi-global license for Arazine, the partnership between Signum Dermalogix and Elizabeth Arden also focuses on the development of new screening methodologies to measure the anti-oxidant potential of other product ingredients used by the latter. 

"With Elizabeth Arden's decades of experience in skin care and our R&D and chemical expertise, we look forward to assisting Elizabeth Arden 's efforts in producing innovative, high quality skin care products supported with robust scientific data," said Dr. Eduardo Perez, vice-president of R&D at Signum Dermalogix.

Related topics: Business & Financial

Related news

Show more